This study (2004) discusses ayahuasca as a possible therapeutic agent and details the challenges that need to be overcome for clinical studies utilizing ayahuasca in the United States to become viable.
Ayahuasca is a hallucinogenic beverage that is prominent in the ethnomedicine and shamanism of indigenous Amazonian tribes. Its unique pharmacology depends on the oral activity of the hallucinogen, N,N-dimethyltryptamine (DMT), which results from inhibition of monoamine oxidase (MAO) by h-carboline alkaloids. MAO is the enzyme that normally degrades DMT in the liver and gut. Ayahuasca has long been integrated into mestizo folk medicine in the northwest Amazon. In Brazil, it is used as a sacrament by several syncretic churches. Some of these organizations have incorporated in the United States. The recreational and religious use of ayahuasca in the United States, as well as ‘‘ayahuasca tourism’’ in the Amazon, is increasing. The current legal status of ayahuasca or its source plants in the United States is unclear, although DMT is a Schedule I-controlled substance. One ayahuasca church has received favorable rulings in 2 federal courts in response to its petition to the Department of Justice for the right to use ayahuasca under the Religious Freedom Restoration Act. A biomedical study of one of the churches, the Uñiao do Vegetal (UDV), indicated that ayahuasca may have therapeutic applications for the treatment of alcoholism, substance abuse, and possibly other disorders. Clinical studies conducted in Spain have demonstrated that ayahuasca can be used safely in normal healthy adults, but have done little to clarify its potential therapeutic uses. Because of ayahuasca’s ill-defined legal status and variable botanical and chemical composition, clinical investigations in the United States, ideally under an approved Investigational New Drug (IND) protocol, are complicated by both regulatory and methodological issues. This article provides an overview of ayahuasca and discusses some of the challenges that must be overcome before it can be clinically investigated in the United States.
Papers cited by this study that are also in Blossom
Callaway, J. C., Mckenna, D. J., Grob, C. S. et al. · Journal of Ethnopharmacology (1999)
Riba, J., Urbano, G., Morte, A. et al. · Psychopharmacology (2001)
Riba, J., Valle, M., Urbano, G. et al. · Journal of Pharmacology and Experimental Therapeutics (2003)
Schwarz, M. J., Houghton, P. J., Rose, S. et al. · Pharmacology Biochemistry and Behavior (2003)
Ayahuasca is a traditional Amazonian psychoactive brew prepared from Banisteriopsis caapi together with DMT-containing admixture plants such as Psychotria viridis. Its unique pharmacology depends on h-carboline alkaloids in B. caapi that inhibit monoamine oxidase A (MAO-A), permitting the normally orally inactive hallucinogen N,N-dimethyltryptamine (DMT) to reach the brain. Use ranges from indigenous shamanic and mestizo ethnomedicine to contemporary syncretic religious practices in Brazil and rising recreational and ritual use internationally. Legal status is ambiguous in some jurisdictions because DMT is a Schedule I substance despite source plants themselves not being explicitly scheduled in many places. Mckenna sets out to review the botany, chemistry, pharmacology, and available biomedical data on ayahuasca, to summarise key clinical investigations (notably a biomedical field study of long-term users, the so-called Hoasca Project), and to discuss the regulatory and methodological challenges that must be addressed before standardised clinical trials—particularly in the United States—can proceed. The paper also proposes a stepwise pathway for preclinical work and clinical development under an Investigational New Drug (IND) framework.
The paper is a narrative review that also presents primary data from the Hoasca Project, a multidisciplinary biomedical investigation of long-term users drawn from the Uniao do Vegetal (UDV) church in Brazil. The field component took place in Manaus in 1993 and involved collaboration among investigators in Brazil, the United States, and Finland; subsequent laboratory analyses were performed at participating academic centres. The Hoasca Project was designed as a pilot study with four principal objectives: to assess acute psychological and physiological effects of hoasca in humans; to characterise serotonergic function in long-term users; to quantify active alkaloids in hoasca tea and in plasma; and to describe pharmacokinetic parameters following ingestion. Subjects for the human component comprised 15 healthy male UDV members who had used hoasca regularly for at least 10 years and a comparison group of 15 age-matched, hoasca‑naive male controls recruited locally. UDV subjects abstained from hoasca for 1 week before some assays. Measures included structured psychiatric diagnostic interviews (Composite International Diagnostic Interview), personality testing (Tridimensional Personality Questionnaire), neuropsychological testing (WHO-UCLA Auditory Verbal Learning Test), a phenomenological assessment of the acute altered state using the Hallucinogen Rating Scale (HRS), and semistructured life‑story interviews for the UDV members. Physiological monitoring comprised heart rate, blood pressure, pupillary diameter, respiration and temperature; neuroendocrine markers measured in plasma included cortisol, prolactin and growth hormone. Pharmacokinetic characterisation used high-performance liquid chromatography of a single standardised batch of hoasca tea prepared by UDV mestres; each subject received an oral dose equivalent to 2 mL/kg body weight. Platelet assays used [3H]-citalopram binding to estimate density (Bmax) and affinity (Kd) of serotonin uptake sites as a peripheral marker of serotonergic transporter regulation. Beyond reporting Hoasca Project methods and results, the paper outlines recommended methodological steps for progressing to regulated clinical research: thorough phytochemical profiling of source plants and standardised freeze-dried extracts, preclinical pharmacology and toxicology in vitro and in animal models, an IND application following FDA botanical guidance, and a staged clinical programme beginning with Phase I safety/tolerability studies in healthy volunteers and proceeding to Phase II efficacy studies in target patient populations such as alcohol dependence.
Hoasca Project — psychological and neuropsychological findings: No current psychiatric diagnoses were found among the 15 long-term UDV members, whereas two control subjects had active psychiatric diagnoses (alcohol misuse and hypochondriasis). Retrospective histories showed that many UDV members had past problems—11 with alcohol misuse, several with prior drug misuse, nicotine addiction or past affective disorders—that had remitted after joining the UDV; members attributed improvements in mental and social functioning to ritual hoasca use. On personality testing, UDV members differed from controls on several Tridimensional Personality Questionnaire dimensions, including indicators of greater regimentation and reduced harm avoidance; on neuropsychological testing the UDV group performed significantly better on word recall and showed trends to better delayed recall and resistance to interference. The Hallucinogen Rating Scale administered to UDV members after ingestion showed subjective effects that were mild compared with intravenous DMT; cluster scores for affect, intensity, cognition and volition approximated those seen with low intravenous DMT doses (around 0.1–0.2 mg/kg), perception comparable to 0.1 mg/kg iv, and somatosensory effects below the lowest comparator dose. Hoasca Project — physiological and neuroendocrine effects: Acute physiological responses to standardized oral hoasca were modest and within normal clinical parameters. Pupillary diameter increased from about 3.7 mm baseline to approximately 4.7 mm at 40 min and remained elevated through 240 min. Heart rate rose from about 71.9 bpm at baseline to a peak of 79.3 bpm by 20 min then fell below baseline before returning toward normal by 240 min. Systolic and diastolic blood pressure peaked at circa 137.3 and 92.0 mm Hg respectively at 40 min and returned to baseline by 180 min. Respiration and temperature showed small fluctuations. Plasma cortisol, growth hormone and prolactin rose markedly after ingestion, with timing delayed relative to injected DMT (cortisol increase at ~60 min, growth hormone at ~90 min, prolactin at ~120 min), consistent with serotonergic agonist action but slower onset due to oral absorption. Hoasca Project — pharmacokinetics and alkaloid quantitation: The hoasca batch used for the study contained (mg/mL) DMT 0.24, THH 1.07, harmaline 0.20 and harmine 1.70. Subjects received a mean dose of about 148.4 mL (2 mL/kg; mean body weight 74.2 kg), corresponding to an average intake per subject of roughly 35.5 mg DMT, 158.8 mg THH, 29.7 mg harmaline and 252.3 mg harmine. Plasma pharmacokinetics were measurable in most but not all participants (emesis likely impaired some measurements). For DMT (n=12), Cmax averaged 15.8 ng/mL at Tmax ≈ 107 min, with an apparent half-life of about 259 min. THH (n=14) reached Cmax 91 ng/mL at ~174 min and showed a prolonged half-life (~532 min). Harmine Cmax was 114.8 ng/mL at ~102 min with T1/2 ≈ 116 min; harmaline Cmax was 6.3 ng/mL at ~145 min and T1/2 was not determined. The slower absorption and lower peak DMT concentrations relative to parenteral administration likely account for less intense subjective effects compared with intravenous DMT. Hoasca Project — serotonergic transporter assay: Platelet [3H]-citalopram binding showed a significant up-regulation of 5-HT transporter density in hoasca drinkers compared with controls (Bmax 993 fmol/mg protein vs 724 fmol/mg protein), with no change in affinity. The significance of peripheral transporter up-regulation as a proxy for central changes is uncertain, but a single-case self-experiment by an investigator reported increased central transporter density on SPECT after six weeks of THH dosing, reversible on discontinuation. Other clinical evidence and safety data: Independent clinical research by Spanish investigators using a freeze-dried standardised ayahuasca preparation in healthy volunteers reported acceptable tolerability and no serious adverse events in dose-response and pharmacokinetic studies. Their electrophysiological work found decrement in sensory gating (auditory P50) but no effect on prepulse inhibition of startle. Overall, both the Brazilian field study and Spanish clinical studies reported no clear evidence of acute or long-term toxicity in controlled settings. The paper also notes widespread anecdotal reports of immune effects and cancer remissions among some users, but emphasises these remain unproven.
Mckenna interprets the assembled evidence as intriguing but preliminary. The combined ethnographic history, the Hoasca Project findings and corroborative clinical work from Spain suggest that, when used in ritualised, supervised contexts, ayahuasca can be administered without overt acute or chronic toxicity in the studied populations and may be associated with lasting positive changes in psychosocial functioning. In particular, the remission of prior alcohol and substance misuse among many long-term UDV members and the observed up-regulation of peripheral serotonin transporters point to a plausible biological mechanism worth further investigation. The authors stress that peripheral platelet transporter changes do not prove corresponding central nervous system changes, and that the causal attribution of behavioural change to biochemical effects of ayahuasca cannot be disentangled from the strong psychosocial and religious context in which the substance was taken. Key limitations acknowledged include the small sample size and nonrandom, observational field nature of the Hoasca Project, potential selection and recall biases, variability in alkaloid content across ayahuasca preparations, and the logistical and regulatory difficulties of conducting such research in the United States. Mckenna emphasises that FDA and DEA regulatory expectations are likely to require comprehensive preclinical pharmacology and toxicology, standardised botanical sourcing with herbarium vouchering, and production of a reproducible freeze-dried extract for IND submission. The paper therefore proposes a staged development pathway: (1) rigorous phytochemical characterisation and preclinical assays to identify active constituents and potential toxicities; (2) IND-enabling studies and standardised extract manufacture; (3) Phase I safety/tolerability studies in healthy volunteers with an open-label dose-escalation design analogous to the Spanish work but timed to mirror potential therapeutic regimens; and (4) Phase II efficacy trials with alcohol dependence identified as the logical initial indication, using clinical outcomes, personality/neuropsychological measures and neuroimaging of serotonin transporter status as endpoints. The authors also recommend exploring immune-modulatory effects in preclinical and clinical assays because of anecdotal reports and ethnomedical claims. Overall, the paper frames further investigation as scientifically warranted but contingent on resolving methodological standardisation and legal/regulatory questions. The authors call for careful, stepwise research conforming to modern phytopharmaceutical and clinical-trial standards rather than uncontrolled or anecdotal use.
Ayahuasca has a well-documented botanical, chemical and ethnographic record, and preliminary biomedical investigations indicate it can be administered in controlled settings without clear acute or chronic toxicity and that it may have therapeutic potential, particularly for substance‑use disorders and conditions associated with serotonergic deficits. Nonetheless, clinical research remains scarce and constrained by variable preparations, limited preclinical data, and unresolved legal and regulatory hurdles. Mckenna concludes that recent field and clinical studies, together with possible legal recognition of ritual use, should provide impetus for rigorous preclinical and clinical programmes to evaluate ayahuasca's safety and therapeutic potential under appropriate regulatory oversight.
Of the numerous plant psychotropics utilized by indigenous populations of the Amazon Basin, perhaps none is as interesting or complex, botanically, chemically, or ethnographically, as the beverage known variously as ayahuasca, caapi, or yage. The beverage is most widely known as ayahuasca, a Quechua term meaning ''vine of the souls,'' which is applied both to the beverage itself and to one of the source plants used in its preparation, the malpighiaceous jungle liana, Banisteriopsis caapi. In Brazil, transliteration of this Quechua word into Portuguese results in the name, hoasca. Hoasca, or ayahuasca, occupies a central position in mestizo ethnomedicine, and the chemical nature of its active constituents and the manner of its use make its study relevant to contemporary issues in neuropharmacology, neurophysiology, and psychiatry.
In a traditional context, ayahuasca is a beverage prepared by boiling-or soaking-the bark and stems of B. caapi together with various admixture plants. The admixture employed most commonly is the Rubiaceous genus Psychotria, particularly Psychotria viridis. The leaves of P. viridis contain alkaloids, which are necessary for the psychoactive effect. Ayahuasca is unique in that its pharmacological activity is dependent on a synergistic interaction between the active alkaloids in the plants. One of the components, the bark of B. caapi, contains h-carboline alkaloids, which are potent monoamine oxidase-A (MAO-A) inhibitors; the other component, the leaves of P. viridis or related species, contains the potent short-acting hallucinogenic agent N,N-dimethyltryptamine (DMT). DMT is not orally active when ingested by itself, but can be rendered orally active when ingested in the presence of a peripheral MAO inhibitor, such as the h-carbolines. This interaction is the basis of the psychotropic action of ayahuasca. There are also reportsthat other Psychotria species are similarly utilized in other parts of the Amazon. In the northwest Amazon, particularly in the Colombian Putumayo and Ecuador, the leaves of Diplopterys cabrerana, a jungle liana in the same family as Banisteriopsis, are added to the brew in lieu of the leaves of Psychotria. The alkaloid present in Diplopterys, however, is identical to that in the Psychotria admixtures, and pharmacologically, the effect is similar. In Peru, various admixtures in addition to Psychotria or Diplopterys are frequently added, depending on the magical, medical, or religious purposes for which the drug is being consumed. Although a virtual pharmacopoeia of admixtures are occasionally added, the most commonly employed admixtures (other than Psychotria, which is a constant component of the preparation) are various Solanaceous genera, including tobacco (Nicotiana sp.), Brugmansia sp., and Brunfelsia sp.. These Solanaceous genera are known to contain alkaloids, such as nicotine, scopalamine, and atropine, which have effects on both central and peripheral adrenergic and cholinergic neurotransmission.
The origins of the use of ayahuasca in the Amazon Basin are unknown. It is uncertain where the practice may have originated, and about all that is certain is that it was already widespread among numerous indigenous tribes throughout the Amazon Basin by the time ayahuasca came to the attention of Western ethnographers in the mid-19th century. This fact alone argues for its antiquity; beyond that, little is known. Plutarco Naranjo, the Ecuadorian ethnographer, has summarized what little information is available on the prehistory of ayahuasca. There is abundant archeological evidence, in the form of pottery vessels, anthropomorphic figurines, snuffing trays and tubes, etc. that plant hallucinogen use was well established in the Ecuadorian Amazon by 1500 -2000 BC. Unfortunately, most of the specific evidence, in the form of vegetable powders, snuff trays, and pipes, is related to the use of psychoactive plants other than ayahuasca, such as coca, tobacco, and the hallucinogenic snuff derived from Anadenanthera species and known as vilka and various other names. There is nothing in the form of iconographic materials or preserved botanical remains that would unequivocally establish the prehistorical use of ayahuasca. It is probable that these pre-Colombian cultures, sophisticated as they were in the use of a variety of psychotropic plants, were also familiar with ayahuasca and its preparation. Recent archaeological evidence has come to lightindicating the existence of a complex, technologically sophisticated riverine/agrarian civilization in the upper Xingu region of Brazil dating at least to 1200 AD. While these discoveries do not directly address the question of the antiquity of knowledge of ayahuasca, they do support the supposition that a complex civilization capable of impacting and actively managing its forest environment for agricultural purposes, would also be likely to be similarly knowledgeable regarding the uses of medicinal species occurring in the ecosystem. The lack of data is frustrating, however, particularly with respect to a question that has fascinated ethnopharmacologists since the late 1960s when its importance was first brought to light through the work of Schultes and his students. As mentioned above, ayahuasca is unique among plant hallucinogens in that it is prepared from a combination of 2 plants: the bark or stems of Banisteriopsis species, together with the leaves of Psychotria species or other DMT-containing admixtures. The beverage depends on this unique combination for its activity. There seems small likelihood of ''accidentally'' combining the 2 plants to obtain an active preparation when neither is particularly active alone, yet we know that at some point in prehistory, this fortuitous combination was discovered. At that point, ayahuasca was ''invented.'' Just how this discovery was made, and who was responsible, we may never know, though several charming myths address the topic. Mestizo ayahuasqueros in Peru will, to this day, say that this knowledge comes directly from the ''plant teachers''. The mestres of the Brazilian syncretic sect, the Un ˜iao do Vegetal (UDV), say with equal conviction that the knowledge came from ''the first scientist,'' King Solomon, who imparted the technology to the Inca king during a little publicized visit to the New World in antiquity. In the absence of data, these explanations are all that we have. All that we can say with confidence is that the knowledge of the techniques for preparing ayahuasca, including knowledge of the appropriate admixture plants, had diffused throughout the Amazon Basin by the time the use of ayahuasca came to the attention of any modern researcher.
The use of ayahuasca under a variety of names is a widespread practice among various indigenous aboriginal tribes endemic to the Amazon Basin. Such practices undoubtedly were well established in pre-Columbian times, and in fact, may have been known to the earliest human inhabitants of the region. Considerable genetic intermingling and adoption of local customs followed in the wake of European contact, and ayahuasca, along with a virtual pharmacopoeia of other medicinal plants, gradually became integrated into the ethnomedical traditions of these mixed populations. Today, the drug forms an important element of ethnomedicine and shamanism as it is practiced among indigenous mestizo populations in Peru, Colombia, and Ecuador. The sociology and ethnography of the contemporary use of ayahuasca in mestizo ethnomedicine has been extensively described.
From the perspective of the sociologist or the ethnographer, discussion of the use of ayahuasca or hoasca can conveniently be divided into a consideration of its use among indigenous aboriginal and mestizo populations, and its more recent adoption by contemporary syncretic religious movements, such as the UDV, Barquinia, and Santo Daime sects in Brazil. It is within the context of acculturated groups such as these that questions regarding the psychological, medical, and legal aspects of the use of ayahuasca become most relevant, and also, most accessible to study. The use of ayahuasca in the context of mestizo folk medicine closely resembles the shamanic uses of the drug as practiced among aboriginal peoples. In both instances, the brew is used for curing, for divination, as a diagnostic tool, and a magical pipeline to the supernatural realm. This traditional mode of use contrasts from the contemporary use of ayahuasca tea within the context of Brazilian syncretic religious movements. (Note: The hoasca religions are ''syncretic'' in that they represent a fusion of indigenous religious practices with elements of Christianity.) Within these groups, the members consume ayahuasca tea at regular intervals in a ritual manner that more closely resembles the Christian Eucharist than the traditional aboriginal use. The individual groups of the UDV, termed nucleos, are similar to a Christian Hutterite sect, in that each group has a limited membership, which then splits to form a new group once the membership expands beyond the set limit. The nucleo consists of the congregation, a group leader or mestre, various acolytes undergoing a course of study and training to become mestres, and a temple. These structures, often circular in layout and beautifully decorated, are the sites where the sacrament is prepared and consumed at prescribed times, usually the first and third Saturday of each month. The membership of these newer syncretic groups spans a broad socioeconomic range and includes many educated, middle-class, urban professionals (including a number of physicians and other health professionals). Some older members have engaged in the practice for 30 or more years without apparent adverse health effects. The UDV and the Santo Daime sects are the largest and most visible of several syncretic religious movements in Brazil that have incorporated the use of ayahuasca into their ritual practices. Of the 2 larger sects, it is the UDV that possesses the strongest organizational structure as well as the most highly disciplined membership. Of all the ayahuasca churches in Brazil, the UDV has also been the most pivotal in convincing the government to remove ayahuasca from its list of banned drugs. In 1987, the government of Brazil approved the ritual use of hoasca teain the context of group religious ceremonies. This ruling has potentially significant implications, not only for Brazil, but for global drug policy, as it marks the first time in over 1600 years that a government has granted permission to its nonindigenous citizens to use a psychedelic substance in the context of religious practices.
The chemical constituents of ayahuasca and the source plants used in its preparation have been well characterized. B. caapi contains the h-carboline derivatives harmine, tetrahydroharmine (THH), and harmaline as the major alkaloids. Trace amounts of other h-carbolines have also been reported, as well as the pyrrolidine alkaloids shihunine and dihydroshihunine(Fig.). The admixture plant, P. viridis, contains a single major alkaloid, DMT, while N-methyl tryptamine and methyl-tetrahydro-h-carboline have been reported as trace constituents. The admixture plant Psychotria carthagenensis has been reported to contain the same alkaloidsbut a subsequent investigation could not confirm the presence of DMT in the single collection examined. The concentrations of alkaloids reported in B. caapi range from 0.05% dry weight to 1.95% dry weight; in Psychotria, the concentration of alkaloids ranged from 0.1% to 0.66% dry weight. Similar ranges and values were reported by both groups of investigators. The concentrations of alkaloids in the ayahuasca beverages are, not surprisingly, several times greater than in the source plants from which they are prepared. Based on a quantitative analysis of the major alkaloids in several samples of ayahuasca collected on the upper Rio Puru ´s,calculated that a 200-mL dose of ayahuasca contained an average of 30 mg of harmine, 10 mg THH, and 25 mg DMT.determined the following concentrations of alkaloids in the hoasca tea utilized in the biomedical study with the UDV (in mg/mL): DMT, 0.24; THH, 1.07; harmaline, 0.20; and harmine 1.70. A typical 100-mL dose of hoasca thus contains (in mg):Interestingly, these concentrations are above the threshold of activity for intravenous administration of DMT.reported somewhat higher values for the alkaloid content of several samples of Peruvian ayahuasca. These investigators calculated that a 100-mL dose of these preparations contained a total of 728 mg total alkaloid, of which 467 mg is harmine, 160 mg is THH, 41 mg is harmaline, and 60 mg is DMT. This is well within the range of activity for DMT administered intramuscularlyor intravenouslyand is also well within the range for harmine to act effectively as a monoamine oxidase inhibitor (MAOI). In vitro, these h-carbolines function as MAOI at f10 nM (e.g., harmine's IC 50 for MAOI is f1.25 Â 10 À8 M; cf.. In mice, harmaline administered intraperitoneally (5 mg/kg) causes 100% inhibition by 2 hr postinjection, the activity falling off rapidly thereafter. This dose corresponds to f375 mg in a 75-kg adult, but, based on the measured concentration of harmine in the liver, it is likely that one-half this dose or less would also be effective. The reasons for the discrepancy in alkaloid concentrations between the samples examined byand those examined byare readily explained by the differences in the methods of preparation. The method employed in preparing ayahuasca in Pucallpa, Peru, where the samples analyzed bywere collected, results in a much more concentrated brew than the method employed on the upper Rio Puru ´s, the region which was the source of the samples examined by Rivier and Lindgren. The concentrations and proportions of alkaloids can vary considerably in different batches of ayahuasca, depending on the method of preparation, as well as the amounts and proportions of the source plants. h-Carbolines, by themselves, may have some psychoactivity and thus may contribute to the overall psychotropic activity of the ayahuasca beverage; however, it is probably inaccurate to characterize the psychotropic properties of hcarbolines as ''hallucinogenic'' or ''psychedelic''. As MAO inhibitors, h-carbolines can increase brain levels of serotonin, and the primarily sedative effects of high doses of h-carbolines are thought to result from their blockade of serotonin deamination. The primary action of hcarbolines in the ayahuasca beverage is their inhibition of peripheral MAO, which protects the DMT in the brew from peripheral degradation and thus renders it orally active. There is some evidence, however, that THH, the second most abundant h-carboline in the beverage, acts as a weak 5-hydroxytryptamine (5-HT) uptake inhibitor and MAOI. Thus, THH may prolong the half-life of DMT by blocking its intraneuronal uptake, and hence, its inactivation by MAO, localized in mitochondria within the neuron. On the other hand, THH may block serotonin uptake into the neuron, resulting in higher levels of 5-HT in the synaptic cleft; this 5-HT, in turn, may attenuate the subjective effects of orally ingested DMT by competing with it at postsynaptic receptor sites.
The psychotropic activity of ayahuasca is a function of the inhibition of peripheral MAO by the h-carboline alkaloids in the mixture. This action prevents the peripheral oxidative deamination of the DMT, which is the primary psychotropic component, rendering it orally active and enabling it to reach its site of action in the central nervous system in an intact form. DMT alone is inactive following oral administration at doses up to 1000 mg. DMT is active by itself following parenteral administration starting at around 25 mg. Because of its oral inactivity, users have employed various methods of parenteral administration. For example, synthetic DMT is commonly smoked as the freebase; in this form, the alkaloid volatilizes readily and produces an immediate, intense psychedelic episode of short duration, usually characterized by multicolored, rapidly moving visual patterns behind the closed eyelids. The Yanomamo Indians and other Amazonian tribes prepare a snuff from the sap of various trees in the genus Virola, which contain large amounts of DMT and the related compound, 5methoxy-DMT, which is also orally inactive. The effects of the botanical snuffs containing DMT, while not as intense as smoking DMT freebase, are similarly rapid in onset and of limited duration. The ayahuasca beverage is unique in that it is the only traditionally used psychedelic where the enzymeinhibiting principles in one plant (h-carbolines) are used to facilitate the oral activity of the psychoactive principles in another plant (DMT). The psychedelic experience that follows ingestion of ayahuasca differs markedly from the effects of parenterally ingested DMT; the time of onset is f35 -40 min after ingestion, and the effects, which are less intense than parenterally administered synthetic DMT, last f4 hr. The subjective effects of ayahuasca include phosphene imagery seen with the eyes closed, dream-like reveries, and a feeling of alertness and stimulation. Peripheral autonomic changes in blood pressure, heart rate, etc., are also less pronounced in ayahuasca than parenteral DMT. In some individuals, transient nausea and episodes of vomiting occur, while others are rarely affected in this respect. When ayahuasca is taken in a group setting, vomiting is considered a normal part of the experience and allowances are made to accommodate this behavior. The amounts of h-carbolines present in a typical dose of ayahuasca are well above the threshold for activity as MAOI. It is likely that the main contribution of the h-carbolines to the acute effects of ayahuasca results from their facilitation of the oral activity of DMT, through their action as MAOI at peripheral sites. It is worthy of note that h-carbolines are highly selective inhibitors of MAO-A, the form of the enzyme for which serotonin, and presumably other tryptamines including DMT, are the preferred substrates. This selectivity of h-carbolines for MAO-A over MAO-B, combined with their relatively low affinity for liver MAO, may explain why no reports have appeared of hypertensive crises or peripheral autonomic stimulation associated with the ingestion of ayahuasca in combination with foods containing tyramine. On the other hand,have reported that DMT is primarily oxidized by MAO-B; it is possible, therefore, that high concentrations of h-carbolines, partially inhibit MAO-B as well as MAO-A; but the greater affinity of tyramine for MAO-B enables it to compete for binding to the enzyme and displace any residual h-carbolines. DMT and its derivatives and h-carboline derivatives are widespread in the plant kingdomand both classes of alkaloids have been detected as endogenous metabolites in mammals, including man. Methyl transferases, which catalyze the synthesis of DMT, 5-methoxy-DMT, and bufotenine, have been characterized in human lung, brain, blood, cerebrospinal fluid, liver, and heart, and also in rabbit lung, toad, mouse, steer, guinea pig, and baboon brains, as well as in other tissues in these species. Endogenous psychotogens have been suggested as possible etiological factors in schizophrenia and other mental disorders, but the evidence remains equivocal. Although the occurrence, synthesis, and degradative metabolism of DMT in mammalian systems has been the focus of scientific investigations, the candidacy of DMT as a possible endogenous psychotogen essentially ended when experiments showed comparable levels in both schizophrenics and normal subjects. At present, the possible neuroregulatory functions of this ''psychotomimetic'' compound are incompletely understood, buthas presented an interesting hypothesis regarding the possible role of endogenous DMT and h-carbolines in regulating sleep cycles and rapid eye movement states. h-Carbolines are tricyclic indole alkaloids that are closely related to tryptamines, both biosynthetically and pharmacologically. They are readily synthesized via the condensation of indoleamines with aldehydes or a-keto acids and their biosynthesis probably also proceeds via similar reactions. h-Carbolines have also been identified in mammalian tissue including human plasma and platelets and rat whole brain, forebrain, arcuate nucleus, and adrenal glands. 6-Methoxy-tetra-Fig.. Biosynthesis of DMT and a tetrahydro-h-carboline from tryptophan. hydro-h-carboline has been recently identified as a major constituent of human pineal gland. This compound inhibits the high-affinity binding of [ 3 H]-imipramine to 5-HT receptors in human platelets, and also significantly inhibits 5-HT binding to 5-HT 1 type receptors in rat brain; the compound has a low affinity to 5-HT 2 receptors, however. 2-Methyltetrahydro-h-carboline and harman have been detected in human urine following ethanol loading,and it was once speculated that endogenous hcarbolines and other amine-aldehyde condensation products might be related to the etiology of alcoholism. At least one h-carboline has been identified as a byproduct of the oxidative metabolism of DMT in rat brain homogenates. h-Carbolines exert a variety of neurophysiological and biological effects. h-Carboline derivatives are selective, reversible, competitive inhibitors of MAO-A. Other neurophysiological actions of h-carbolines include competitive inhibition of the uptake of 5-HT, dopamine, epinephrine, and norepinephrine into synaptosomes, inhibition of Na + -dependent membrane ATPases, interference with biosynthesis of biogenic amines, and vasopressin-like effects on sodium and water transport in isolated toad skin. h-Carboline-3-carboxylate and various esterified derivatives have been implicated as possible endogenous ligands at benzodiazepine receptors. h-Carboline ligands of these receptors can induce epileptiform seizures in rats and in chickens homozygous for the epileptic gene; this proconvulsant action can be blocked by other receptor ligands, including diazepam and h-carboline-carboxylate propyl ester. h-Carbolines also exhibit other biological activities in addition to their effects on neurophysiological systems. For instance,found that harmine exhibited significant anti-trypanosomal activity against Trypanosoma lewisii. This finding may explain the use of ayahuasca in mestizo ethnomedicine as a prophylactic against malaria and internal parasites. Certain h-carbolines are known to exert mutagenic or co-mutagenic effects and the mechanism responsible may be related to their interactions with nucleic acids. The UV light-activated photocytotoxic and photogenotoxic activity of some h-carbolines has also been reported.
Although achieving some notoriety in North American literature through the popular press and the writings of, the psychological and physiological phenomena induced by ayahuasca have received little rigorous study. Various travelers to the Amazon have reported their own first hand experiences with ayahuasca, while both formal and informal ethnographic narratives have excited the public imagination. Interest in the exotic origins and effects of ayahuasca have attracted a steady stream of North American tourists, often enticed by articles and advertisements in popular and New Age magazines. Concern over possible adverse health effects resulting from the use of ayahuasca by such naive travelers has recently been expressed by a noted authority on mestizo ayahuasca use (Dobkin de Rios, 1994). These concerns are in marked contrast to testimonials of improved psychological and moral functioning by the adherents of the syncretic hoasca churches in Brazil. The individuals who are attracted to the UDV seem to belong to a somewhat more educated socioeconomic class than those who join the Santo Daime. Of the f7000 members of the UDV in Brazil, perhaps 5-10% are medical professionals, among them physicians, psychiatrists, psychologists, chiropractors, and homeopathic physicians. Most of these individuals are fully aware of the psychologically beneficial aspects of the practice and evince a great interest in the scientific study of hoasca, including its botany, chemistry, and pharmacology. The medically educated members can discuss all of these aspects with sophistication equal to that of any US-trained physician or other medical professional. At the same time, they do have a genuine spiritual reverence for the hoasca tea and the experiences it evokes. The UDV places a high value on the search for scientific truth and sees no conflict between science and religion; most members of the UDV express a strong interest in learning as much as possible about how the tea acts on the body and brain. As a result of this unique circumstance, the UDV presents an ideal context in which to conduct a biomedical investigation of the acute and longterm effects of hoasca/ayahuasca.
Due to a fortunate combination of circumstances, my colleagues and I were invited to conduct such a biomedical investigation of long-term hoasca drinkers by the Medical Studies section of the UDV (Centro de Estudos Medicos). This study, which was conducted by an international consortium of scientists from Brazil, the United States, and Finland, was financed through private donations to various nonprofit sponsoring groups, notably Botanical Dimensions, which provided major funding, the Heffter Research Institute, and the Multidisciplinary Association for Psychedelic Studies. Botanical Dimensions is a nonprofit organization dedicated to the study and preservation of ethnomedically significant plants, and the Multidisciplinary Association for Psychedelic Studies () and the Heffter Research Institute () are nonprofit organizations dedicated to the investigation of the medical and therapeutic uses of psychedelic agents. The field phase of the study was conducted during the summer of 1993 at one of the oldest UDV temples, the Nucleo Caupari located in the Amazonian city of Manaus, Brazil. Subsequent laboratory investigations took place at the respective academic institutions of some of the principle investigators, including the Department of Psychiatry, Harbor UCLA Medical Center, the Department of Neurology, University of Miami School of Medicine, the Department of Psychiatry, University of Rio de Janeiro, Department of Internal Medicine, University of Amazonas Medical School, Manaus, and the Department of Pharmaceutical Chemistry, University of Kuopio, Finland. This study has since become anecdotally known as ''the Hoasca Project'' in subsequent presentations of the results in various public venues. Because this study was the first of its kind, there was virtually no preexisting data on the objective measurement of the physical and psychological effects of ayahuasca in human subjects. As a result, this study was in some respects a pilot study; its primary objectives were modest, representing an effort to collect a basic body of data, without attempting to relate the findings to either possible detrimental effects of ayahuasca, or to possible therapeutic effects. The study had 4 major objectives: Assessment of acute psychological and physiological effects of hoasca in human subjects; Assessment of serotonergic functions in long-term users of hoasca tea; Quantitative determination of active constituents of hoasca teas in plasma; Quantitative determination of active constituents of hoasca teas. Most of these objectives were achieved, and the results have been published in various peer-reviewed scientific journals. Some key findings are summarized briefly below.
The subjects in all of the studies consisted of a group of 15 healthy, male volunteers, all of whom had belonged to the UDV for a minimum of 10 years, and who ingested hoasca once every 2 weeks, on average, in the context of the UDV ritual. None of the subjects actively used tobacco, alcohol, or any drugs other than hoasca. For some comparative aspects of the study, a control group of 15 age-matched males was also used; these individuals were recruited from among the friends and siblings of the volunteer subjects, and like them, were local residents of Manaus having similar diets and socioeconomic status. None of the control subjects were members of the UDV, and none had ever ingested hoasca tea. The psychological assessments, administered to both groups, consisted of structured psychiatric diagnostic interviews, personality testing, and neuropsychological evaluations. Measures administered to the UDV hoasca drinkers, but not to the hoasca-naive group, included semistructured and open-ended life story interviews. A phenomenological assessment of the altered state elicited by hoasca was quantified using the Hallucinogen Rating Scale developed by Dr. Rick Strassman in his work with DMT and psilocybin in human subjects. The UDV volunteers showed significant differences from the hoasca-naive subjects in the Tridimensional Personality Questionnaire and the WHO-UCLA Auditory Verbal Learning Test. The Tridimensional Personality Questionnaire assesses 3 general areas of behavior, viz., novelty-seeking, harm avoidance, and reward dependence. With respect to novelty-seeking behaviors, UDV members were found to have greater stoic rigidity versus exploratory excitability, greater regimentation versus disorderliness, and a trend toward greater reflection versus impulsivity; but there was no difference between the groups on the spectrum between reserve and extravagance. On the harm reduction scale, UDV subjects had significantly greater confidence versus fear of uncertainty and trends toward greater gregariousness versus shyness and greater optimism versus anticipatory worry. No significant differences were found between the 2 groups in criteria related to reward dependence. The 15 UDV volunteers and the control subjects were also given the WHO-UCLA Auditory Learning Verbal Memory Test. Experimental subjects performed significantly better than controls on word recall tests. There was also a trend, although not statistically significant, for the UDV subjects to perform better than controls on number of words recalled, delayed recall, and words recalled after interference. The Hallucinogen Rating Scale, developed byfor the phenomenological assessment of subjects given intravenous doses of DMT, was administered to the UDV volunteers only (since control subjects did not receive the drug). All of the clinical clusters on the HRS were in the mild end of the spectrum compared with intravenous DMT. The clusters for affect, intensity, cognition, and volition were comparable to an intravenous DMT dose of 0.1 -0.2 mg/kg, and the cluster for perception was comparable to 0.1 mg/kg iv DMT; the cluster for somatesthesia was less than the lowest dose of DMT measured by the scale, 0.05 mg/kg. The most striking findings of the psychological assessment came from the structured diagnostic interviews and the semistructured open-ended life story interviews. The Composite International Diagnostic Interview was used for the structured diagnostic interview. None of the UDV subjects had a current psychiatric diagnosis, whereas 2 of the control subjects had an active diagnosis of alcohol misuse and hypochondriasis. Only 1 subject among the controls had a past psychiatric disorder that was no longer present; an alcohol misuse disorder that had remitted 2 years previously. However, prior to membership in the UDV, 11 of the UDV subjects had diagnoses of alcohol misuse disorders, 2 had past major depressive disorders, 4 had past histories of drug misuse (cocaine and amphetamines), 11 were addicted to tobacco, and 3 had past phobic anxiety disorders. Five of the subjects with a history of alcoholism also had histories of violent behavior associated with binge drinking. All of these pathological diagnoses had remitted following entry into the UDV. All of the UDV subjects interviewed reported the subjective impression that their use of hoasca tea within the context of the UDV had led to improved mental and physical health and significant improvements in interpersonal, work, and family interactions.
The major focus of the biochemical and physiological measurements carried out for the study was on the acute effects subsequent to consuming hoasca tea. One of the objectives was simply to measure the effects of hoasca on standard physiological functions, such as heart rate, blood pressure, and pupillary diameter, subsequent to ingestion. We found that all of these responses were well within normal parameters. Hoasca, not surprisingly, caused an increase in pupillary diameter from baseline (predose) levels of 3.7 to f4.7 mm at 40 min, which continued to 240 min after ingestion, at which point measurements were discontinued. Respiration rate fluctuated throughout the 240 min, from a low of 18.5 at baseline to a high of 23 at 100 min. Temperature rose from a baseline low of 37 jC at baseline to a high of 37.3 jC at 240 min (although the ambient temperature also increased comparably during the course of the experiments, which were conducted from 10:00 to 16:00 h). Heart rate increased from 71.9 bpm at baseline to a maximum of 79.3 bpm by 20 min, decreased to 64.5 bpm by 120 min, then gradually returned toward basal levels by 240 min. There was a concomitant increase in blood pressure; both systolic and diastolic pressure increased to maxima at 40 min (137.3 and 92.0 mm Hg, respectively) over baseline valuesand returned to basal values by 180 min. We also measured neuroendocrine response for plasma prolactin, cortisol, and growth hormone; all showed rapid and dramatic increases over basal values from 60 (cortisol) to 90 (growth hormone) to 120 min (prolactin) after ingestion. The observed response is typical of serotonergic agonists, and is comparable to the values reported byin response to injected DMT. In our study, the neuroendocrine response to oral DMT was delayed by a factor of 4 or 5 compared with the almost immediate (<15 min) response to injected DMT.
The fourth objective of the study was to measure pharmacokinetic parameters of the hoasca alkaloids in plasma following ingestion of hoasca tea and to correlate this to the amounts of alkaloids ingested. The UDV collaborators held a special ''preparo'' to prepare the sample of hoasca that was used for all subjects in the study. The mestres confirmed the activity in the usual manner, via ingestion, and pronounced it active and suitable for use in the study. Subsequent analysis by high-performance liquid chromatography found the tea to contain (in mg/mL): harmine, 1.7; harmaline, 0.2; THH, 1.07; and DMT 0.24. Each subject received an aliquot of tea equivalent to 2 mL/kg body weight, which was consumed in a single draught. Based on the average body weight (74.2 F 11.3 kg), the average dose of tea was 148.4 F 22.6 mL, containing an average of 35.5 mg DMT, 158.8 mg THH, 29.7 mg harmaline, and 252.3 mg harmine. These doses are above the threshold level of activity for DMT as a psychedelic, and for harmine and THH as MAO inhibitors; harmaline is essentially a trace constituent of hoasca tea. Only 12 of the 15 volunteers had sufficient plasma levels of DMT to permit pharmacokinetic measurements, possibly due to early emesis during the course of the session. Of these, the maximum plasma concentration (C max ; 15.8 ng/ mL) occurred at 107 min after ingestion, while the half-life (T 1/2 ) was 259 min. THH was measured in 14 of the 15 subjects; the C max was 91 ng/mL, which was reached at 174 min. This compound displayed a prolonged half-life of 532 min, in contrast to harmine, which had a half-life of 115.6 min. The C max for harmine and harmaline was 114.8 and 6.3 ng/mL, respectively, and time of maximum concentration (T max ) was 102 and 145 min, respectively. The T 1/2 for harmaline could not be measured. This study was conceived because of the need to collect some basic data on the physiological and pharmacokinetic characteristics of hoasca, since none had existed previously. The conclusions to be drawn from the results, if any, are interesting and potentially significant, particularly in that these findings may offer a physiological rationale for the marked improvements in psychological health that are correlated with long-term hoasca use. Not surprisingly, the highest plasma concentrations of DMT correlated with the most intense subjective effects; however, the psychological measurement (Hallucinogen Rating Scale) indicated that comparable plasma levels of injected DMT instudy resulted in a more intense subjective experience than the effects reported from the hoasca tea. One possible explanation is that THH, by acting as a 5-HT reuptake inhibitor, may have resulted in a greater availability of 5-HT at the synapse, and this may have competed with DMT for occupancy at serotonergic synapses. Alternatively, the rapid increase in brain levels of DMT following intra-venous administration may result in a more intense subjective effect compared with that experienced when DMT is absorbed more slowly following oral administration. Another point worthy of remark is that the activity of THH in hoasca is apparently more a function of its inhibition of 5-HT uptake than to its MAOI action. THH is a poor MAOI compared with harmine (EC 50 = 1.4 Â 10 À5 M for THH vs. 8 Â 10 À8 M for harmine), and while the plasma levels for harmine are well above the EC 50 values, those for THH are well below the EC 50 value for this compound as an MAOI.
Another objective of the study was to investigate whether long-term use of hoasca resulted in any identifiable ''biochemical marker'' that was correlated with hoasca consumption, particularly with respect to serotonergic functions, since the hoasca alkaloids primarily affect functions mediated by this neurotransmitter. Ideally, such a study could be carried out on postmortem brains; since this was not possible, we settled on looking at serotonin transporter sites in blood platelets, using [ 3 H]-citalopram to label the transporters in binding assays (Table). The up-or down-regulation of peripheral platelet recognition sites has been proposed to be indicative of similar biochemical events occurring in the brain, although there is some controversy about the correlation between platelet transporter changes and changes in central nervous system transporters in patients receiving antidepressant medications;. However, platelet-binding assays were deemed suitable for the purposes of our study, as our objective was not to resolve this controversy but simply to determine if some kind of long-term biochemical marker could be identified. Neither did we postulate any conclusions about the possible ''adverse'' or ''beneficial'' implications of such a marker, if detected. We conducted the assays on platelets collected from the same group of 15 volunteers after they had abstained from consuming the tea for a period of 1 week. We also collected platelet specimens from the age-matched controls who were not hoasca drinkers. We were surprised to find a significant up-regulation in the density of the citalopram binding sites in the hoasca drinkers compared with control subjects. Although the hoasca drinkers had a higher density of transporters (B max = 993 fmol/mg protein in hoasca drinkers vs. 724 fmol/mg protein in matched controls; cf. Table), there was no change in their affinity for the labeled citalopram binding site. The significance of this finding, if any, is unclear. There is no other pharmacological agent that is known to cause a similar up-regulation, although chronic administration of 5-HT uptake inhibitors has been reported to decrease both B max (the density of binding sites)and 5-HT transporter mRNA in rat brain. Increases in B max for the uptake site in human platelets have been correlated with old ageand also to the dark phase of the circadian cycle in rabbits. It has been speculated) that up-regulation of 5-HT uptake sites in the aged may be related to the natural course of neuronal decline. Although our sample size was limited, we found no correlation with age, and the mean age of the sample was 38 years. Also, none of our subjects showed evidence of any neurological or psychiatric deficit. In fact, in view of their exceptionally healthy psychological profiles, one of the investigators speculated that perhaps the serotonergic upregulation is associated, not simply with age, but with ''wisdom''-a characteristic often found in the aged, and in many hoasca drinkers. Another interesting self-experiment related to this finding was carried out by one of the investigators, Jace Callaway, following his return to Finland after the field phase of the study was completed. Dr. Callaway has access to single photon emission computerized tomography scanning facilities in the Department of Pharmacology at the University of Kuopio. Suspecting that the causative agent of the unexpected up-regulation might be THH, Dr. Callaway took single photon emission computerized tomography scans of his own brain 5-HT uptake transporters prior to beginning a 6-week course of daily dosing with THH, repeating the scan after the treatment period. He found that the density of central 5-HT receptors in the prefrontal cortex had increased; when he discontinued THH, their density gradually returned to previous levels over the course of several weeks. While this experiment only had 1 subject, if it is indicative of a general effect of THH that can be replicated and confirmed, the implications are potentially significant. A severe deficit of 5-HT uptake sites in the frontal cortex has been found to be correlated with aggressive disorders in violent alcoholics; if THH is able specifically to reverse this deficit, it may have applications in the treatment of this syndrome. These findings are especially interesting when viewed in the context of the psychological data collected in the hoasca study. The majority of the subjects had had a previous history of alcoholism, and many had displayed violent behavior in the years prior to joining the UDV; virtually all attributed their recovery and change in behavior to their use of hoasca tea in the UDV rituals. While it can be argued that their reformation was due to the supportive social and psychological environment found within the UDV, the finding of this long-term change in precisely the serotonin system that is deficient in violent alcoholism argues that biochemical factors may also play a role.
In recent decades, ayahuasca has been integrated into the religious practices of several syncretic religions in Brazil, where it is consumed as a sacrament in large group rituals, sometimes involving up to several hundred people. There are 3 primary Brazilian religions that employ ayahuasca as a sacrament: the UDV, the Santo Daime, and the Barquinia. The Santo Daime and UDV churches include about 10,000 members each throughout Brazil. The Barquinia is a smaller group, consisting of only a few hundred members, primarily in the Rio Branco area of the Amazon. The religious practices of these groups, and their sacramental use of ayahuasca, are sanctioned and legally permitted by CON-FEN, the Brazilian regulatory agency that fulfills a role similar to the FDA and DEA in this country. Ayahuasca and its source plants are not internationally prohibited under the 1971 Convention on Psychotropic Substances although one of them contains a Schedule I controlled substance, DMT. The source plant B. caapi contains hcarboline alkaloids, which are not listed as controlled substances either internationally or in the United States, so the controversy centers around the occurrence of DMT in the admixture plant, P. viridis, or other DMT-containing admixtures that may occasionally be substituted for P. viridis. Pure DMT is a Schedule I controlled substance under US law and is listed as a controlled substance under the International Convention on Psychotropic Substances. However, neither P. viridis nor any of the numerous other plant species that are known to containare specifically controlled or regulated as controlled substances. Many of these plants are freely and legally available from Internet web sites and elsewhere. A recent opinion letter was issued by Herbert Schaepe, the Secretary of the Board for the United Nations International Narcotics Control Board (INCB) that has been helpful in clarifying at least the international legal status of plants containing DMT and other hallucinogens. In No plants (natural materials) containing DMT are at present controlled under the 1971 Convention on Psychotropic Substances. Consequently, preparations (e.g., decoctions) made of these plants, including ayahuasca, are not under international control, and, therefore, not subject to any of the articles of the 1971 convention. A copy of this letter was submitted in support of a suit filed by the North American chapter of the UDV seeking a preliminary injunction against attempts by the Department of Justice to suppress the group's religious use of hoasca (see below). The UDV and Santo Daime churches that originated in Brazil now have legally incorporated American chapters that use ayahuasca in religious ceremonies. In November 2000, the US chapter of the UDV, based in Santa Fe, petitioned the Department of Justice in the US District Court for the District of New Mexico for the return of some 30 gal of its sacramental hoasca. This material had been seized by the DEA from the home of the UDV leader in May 1999. The UDV appealed for a special exemption to allow for the religious use of ayahuasca under the provisions of the Religious Freedom Restoration Act (see. com/cd/nss-folder/pubfiles/PltnfsComplaint.pdf) (O Centro Espirita Beneficiente. A favorable ruling by that court in 2002 allowed for the religious use of hoasca tea by the UDV Church (US District Court for the District of New Mexico: No CV 00-1647 JP/LRP (see ''Federal Court Rules in Favor of Ayahuasca-Using Church,''; Center for Cognitive. The government filed an emergency stay, and the favorable ruling was temporarily contravened (seenss-folder/pubfiles/emerstay.htm). In September 2003, a 3-judge review panel in the 10th US Circuit Court of Appeals in Denver again returned a ruling in favor of the UDV. The ultimate resolution of this case remains pending and may eventually require review by the US Supreme Court. A complete chronology of this case and links to relevant public documents filed in the process can be found on the web site of the Center for Cognitive Liberty and Ethics (. cognitiveliberty.org/dll/udv _ index.htm). Although the ultimate outcome of the UDV's efforts to secure legal sanction for their religious use of ayahuasca may entail years of litigation, it is clear that increasing numbers of people in the United States are using ayahuasca on a regular basis in rituals and in religious ceremonies. The growing use of ayahuasca for religious (and recreational) purposes in the United State has public health implications. Additionally, the growth of ''ayahuasca tourism'' in the Amazon is attracting increasing numbers of American and foreign travelers. The uncertain legal and regulatory status under US law of ayahuasca, or more specifically, its DMT-containing component, P. viridis, also may pose challenges for the eventual pursuit of clinical investigations of ayahuasca under an Investigational New Drug (IND) application.
There are currently 2 primary rationales supporting the need for controlled clinical investigations of ayahuasca: 1. Ayahuasca is becoming increasingly popular in this country for both religious and recreational purposes. The currently pending legal challenges to the religious use of ayahuasca, described above, have so far resulted in rulings favorable to the UDV, the religious organization that has petitioned the government for the legal right to employ ayahuasca as a sacrament under the Religious Freedom Restoration Act. This raises the possibility that religious use of ayahuasca may eventually become legally sanctioned in the United States. Yet, increasing use of ayahuasca, whether ritually or recreationally, has public health implications. Despite a long history and tradition of indigenous use that indicates that the preparation can be used safely, very little actual clinical data have been accumulated, which provides a scientific basis for the notion that ayahuasca is safe for human use. Such studies are needed to inform the currently pending legal challenges to its use for religious purposes. In addition, such studies would provide health professionals with a body of information as to its safety, possible side effects, potential drug interactions, potential for adverse reactions, and possible toxicity. Such data may be essential for health providers in the event they are required to treat individuals who have ingested ayahuasca. 2. A second rationale is that ayahuasca may have therapeutic applications, and these require investigation within the context of well-designed clinical studies. Ideally, such studies should be conducted under an FDAapproved IND protocol, together with whatever regulatory permissions are required from the DEA and an institutional IRB affiliated with the institution where the study is to be conducted.
11.1. Key findings from the ''Hoasca Project''studied the short-and long-term toxicity profile of hoasca use in the Brazilian UDV. They reported that there was no evidence of acute toxicity during the sessions or of long-term toxicity or other adverse health effects. Hoasca, in the context of the UDV, is consumed regularly by men and women ranging in ages from 13 to 90 and appears to be safe. Many of the older members of the UDV, who are now well into their 80s, have used hoasca regularly since their teenage years and are remarkable for their mental acuity, lack of serious disease history, and physical vigor. Psychological screening tests and evaluations have found no evidence of long-term mental or cognitive impairment in long-term hoasca drinkers (UDV members). In fact, most members performed slightly better than control subjects on measures of cognitive function, verbal facility and recall, mathematical ability, motivation, and emotional well-being and personality adjustment. The study protocol included the psychological assessment of 15 long-term UDV members utilizing hoasca as a legal, psychoactive sacrament, as well as 15 matched controls with no prior history of hoasca ingestion. Measures administered to both groups included structured psychiatric diagnostic interviews, personality testing, and neuropsychological evaluation. Overall assessment revealed high functional status. Implications of these findings and the need for further investigation are discussed. In addition to psychological parameters, the study included pharmacokinetic measurements of the major active alkaloids. Three key findings have emerged from the study, which has come to be known as the ''Hoasca Project.'' These have been described in detail in the previous sections.
Two kinds of evidence argue that ayahuasca may have therapeutic applications. A considerable body of anecdotal evidence, coupled with a long history of ethnomedical use, indicates that ayahuasca may be useful for the treatment of abuse disorders, such as alcoholism and substance abuse, as well as for physical maladies such as cancer. In addition, the results of a 1993 biomedical study of long-term members of the UDV in Brazil have provided data that may indicate directions for the future direction of clinical studies of ayahuasca.
In the right circumstances, meaning within appropriate supportive settings and social milieus such as the Brazilian UDV, regular and long-term hoasca use may result in profound, lasting, and positive behavioral and lifestyle changes. The most dramatic example is the finding that, prior to their joining the UDV church, most members that were interviewed had histories of alcoholism, substance abuse, domestic violence, and other maladaptive behaviors and lifestyles. These dysfunctional behaviors resolved themselves on subsequent induction into the UDV and regular use of the hoasca sacrament. Dr. Micheal Winkelman coined the term psychointegrator plants for describing the psychological benefits of ayahuasca administration. There is increasing interest in shamanistic forms of healing and ayahuasca's reputed psychological, medical, and spiritual benefits have stirred interest among North American scientists, physicians, and the intellectual lay public. Many North Americans and Europeans travel to the Amazon to participate in ayahuasca ceremonies led by traditional shamans (also called ayahuasqueros) (Dobkin de. A recent report on BBC radio (grammes/crossing_continents/3243277.stm) discusses the successful use of ayahuasca to treat cocaine addition at a Peruvian clinic. The results of the Hoasca study, described above, also argue that ayahuasca treatment, within an appropriate psychotherapeutic context, may also be applicable to the treatment of alcoholism.
Coupled with these positive psychological and behavioral changes, was an unexpected finding. Apparently, regular ayahuasca use results in a long-term modulation of serotonin systems in the brain; specifically, that populations of serotonin transporters exhibit an elevated density in platelets and in the brain, an effect that may be due to one of the h-carbolines in the ayahuasca mixture (see Table). The parameter measured in the hoasca study was an elevation in the density of 5-HT transporters in platelets, and did not directly measure brain levels. However, psychopharmacologists have long-used platelets as a peripheral marker of similar biochemical events occurring within the brain. The serotonin transporter is the membrane bound protein in serotonin containing neurons that manages the reuptake of this neurotransmitter from the synapse, and is the site of action of Prozac and other selective serotonin reuptake inhibitors. Hence, the 5-HT transporter is intimately involved with syndromes such as depression and other mood disorders, suicidal behavior, etc..have hypothesized that the elevation of 5-HT transporters seen with long-term ayahuasca use and the positive behavioral changes are linked. Work by other investigators have found severe deficits in the density of these transporters in people with behavioral disorders, especially patients with a history of alcoholism linked with violence, and in those prone to suicidal behavior. Based on our finding that 5-HT transporters are significantly elevated in long-term users of ayahuasca, we speculate that ayahuasca may be able to reverse these deficits over time. Serotonergic deficits have been linked to a variety of functional, behavioral, and neurodegenerative disorders, ranging from alcoholism to depression, autism, schizophrenia, attention deficit hyperactivity disorder, and senile dementias. Recent advances in the cloning of neurotransmit-ter transporter genes and the development of transporterdeficient knockout mice have given neurobiologists powerful new tools for investigating the role of monoamine transporters in the regulation of neurotransmitter functions and their potential links to neurobiological and behavioral disorders. Genetic polymorphisms in transporter genes and their expression have been linked to anxiety states, autism, affective disorders, and alcohol and cocaine abuse. The results from the UDV study indicate that one or more constituents in ayahuasca may be able to modulate gene expression for the serotonin transporters and that the long-term changes observed are correlated with positive behavioral changes. If these preliminary findings are borne out by more rigorous clinical studies neurobiologists may have a new compound that may be applied to the study of serotonin transporter expression and regulation. Eventually, compounds developed form this work may yield new treatments for substance abuse and psychiatric disorders.
The third piece of evidence that has emerged is more anecdotal than scientific, but is nonetheless intriguing. This is that ayahuasca may have significant immunomodulatory effects. A number of users of ayahuasca in North America have reported that they have experienced remissions of cancers and other serious illnesses in conjunction with regular use of the tea. Additionally, the longevity, physical vigor, and mental acuity evidenced by many ayahuasqueros in Peru has long been noted as remarkable. Many of these shamans living in developing nations are well into their 70s, 80s, and 90s and yet appear to live out their years in a state of physical and mental health that would be the envy of many in the so-called developed countries. Certainly, some of this is due to dietary factors and a physically vigorous and demanding lifestyle; but some of it may be the result of exceptional immune functions due to their years of working with ayahuasca. Many of these practitioners are accustomed to consuming it several times a week in the performance of their healing practices and have done so most of their adult lives. In the context of mestizo folk medicine and indigenous shamanic practice, ayahuasca has long enjoyed a reputation as a healing medicine, with properties that transcend its acute, psychological effects. These properties may be attributable to its immune potentiating effects, if they are found to exist. Although the evidence at this point is anecdotal and speculative, this hypothesis can be easily resolved empirically. Many plants are known to possess immune-potentiating properties and both in vivo and in vitro methodologies have been developed to measure the immune-modulating properties of plant extracts. A recent study characterized the immunopotentiating and antitumor properties of another well-known indigenous hallucinogen, the peyote cactus.
Subsequent to the completion of the ''Hoasca Project'' and the publication of its results, a group of investigators at the Universitat Autonoma de Barcelona in Spain have conducted clinical investigations examining various aspects of the pharmacology of ayahuasca in healthy volunteers. Using a freeze-dried, preparation of Brazilian ayahuasca standardized to contain known quantities of DMT and hcarboline alkaloids, these investigators initially conducted safety assessments and dose-response studies in a small sample of healthy volunteers. After documenting physiological and subjective changes induced by the lyophilized ayahuasca preparation, the investigators concluded that it was well tolerated and presented an acceptable side-effect profile. Subsequent investigations focused on characterization of the pharmacokinetic profiles and effects on cardiovascular parameters. Electrophysiological and psychological effects were investigated using topographic pharmaco-EEG mapping,, while effects on the startle reflex and sensory and sensorimotor gating were assessed using suppression of the P50 auditory evoked potential and prepulse inhibition of the startle reflex. In contrast to studies with other psychedelic agents, such as psilocybin, these investigators found a decremental effect on sensory gating as measured by the auditory evoked potential and a lack of effect on sensorimotor gating measured by prepulse inhibition. More relevant, perhaps, to the immediate concerns regarding the safety of using ayahuasca in humans are that no serious adverse reactions, evidence of toxicity, or lack of tolerability was experienced by the subjects over the series of studies.
There exists both a need and an opportunity to investigate these questions in a more rigorous scientific framework that conforms to currently accepted medical paradigms for conducting clinical research. The evidence from the Brazilian UDV study is intriguing, but not compelling; the sample of subjects studied was small, and given the exigencies of conducting this kind of research in a foreign country and a nonclinical venue, inevitably many factors could not be controlled. Additionally, the question of immune potentiation has yet to be investigated in any manner beyond anecdotal reports and casual observations. The safety and efficacy of ayahuasca has not been definitively verified, and safety concerns in the United States grow as use of ayahuasca as a spiritual sacrament grows. The American medical community will insist, rightly so, on more rigorous inves-tigations in the form of controlled clinical trials before any possible therapeutic investigations can proceed. A number of hurdles must be overcome before ayahuasca can be studied in a clinical context in the United States. First of all, a clarification of its legal status is needed to determine what kinds of permissions, if any, are needed from the DEA and other relevant law-enforcement agencies to pursue clinical studies. Although the opinion issued by the Secretary for the UN Narcotics Control Boardindicates that neither the preparation nor the source plants are internationally regulated, the status of ayahuasca under US law remains in limbo. The UDV's case for an exemption for the sacramental use of hoasca under the Religious Freedom Restoration Act has received favorable rulings in 2 Federal courts and appeal to the Supreme Court is likely. It is to be hoped that a favorable resolution in this case will simplify the regulatory challenges to biomedical studies of ayahuasca.
Assuming the regulatory dilemmas are eventually resolved, it remains unlikely that the FDA will approve an initial IND application for a clinical study without an extensive body of data derived from preclinical investigations. Although the clinical studies byandhave produced evidence that ayahuasca can be used safely in a clinical setting, FDA regulators may insist on generating preclinical data within the United States. Ayahuasca has been poorly studied in animal models, and such a requirement on the part of the FDA could contribute to better quality research in subsequent clinical phases. Many of the questions relating to the understanding of ayahuasca's pharmacology can and should be addressed first in appropriate in vitro and animal models. The results of those preclinical studies will then be useful in terms of framing and focusing subsequent clinical studies. Ayahuasca, like all botanical medicines, is a complex combination of hundreds, or perhaps even thousands, of biologically active compounds. Although there have been extensive phytochemical investigations of ayahuasca over the years, almost all of them have focused exclusively on the alkaloids, since they are the psychoactive constituents. Not even all of the alkaloids have been investigated thoroughly; for example, the pharmacology of the pyrrolidine alkaloids shihunine and dihydroshihunine in B. caapi remains a black box although the compounds were isolated over 30 years ago. Ayahuasca and its source plants are likely to contain flavonoids, tannins, lignans, saponins, volatile oils, and many of the other classes of secondary metabolites that are widespread in plants. All of these have enormous molecular diversity and all have been shown to posses an equally wide spectrum of pharmacological activities. None of those in ayahuasca, however, have been investigated from this perspective. Ad-ditionally, much of the early phytochemical work and preclinical pharmacology on Banisteriopsis extracts was conducted over 30 years ago. There have been important advances in both phytochemical analysis methods and preclinical pharmacology since this work was carried out, and there is a need to revisit these questions using more current methodologies. A thorough phytochemical characterization of ayahuasca and its source plants then becomes the first order of business for any preclinical studies. Extracts of each plant should be made and fractionated using standard phytochemical procedures. The biological activities of the fractions can be further characterized using appropriate in vitro assays. These investigations will provide guidance for further studies in animal models and eventually in clinical trials; it may also detect activities, even toxicity, that is currently unsuspected or uncharacterized. It is important that these investigations be conducted using source plants of known provenance, documented by herbarium voucher collections, so that the data will be applicable to the development of a standardized preparation for eventual use in INDauthorized clinical studies. Preclinical studies will also enable investigators to examine aspects of ayahuasca's pharmacology that may be relevant to its suspected therapeutic activity. For example, a recent in vitro investigation reported activities in Banisteriopsis extracts potentially relevant to the treatment of Parkinson's diseasein which the h-carboline components alone did not sufficiently account for all of the observed activity. Techniques, such as in vitro receptor binding and autoradiography, can be applied to characterize the effects of ayahuasca alkaloids and extracts on modulation of the serotonin transporter and other neurobiological functions. Similarly, questions about the possible immune-potentiating effects of ayahuasca can be initially addressed in animal or in vitro test systems. Relatively standard in vitro and in vivo techniques for measuring immune response have been applied to a variety of medicinal plants (cf..
The phytochemical profiling and preclinical pharmacological and toxicological data generated in the preclinical phase will lay the foundation for the IND application. The FDA has issued a draft of guidelines, still under review, for the development of botanical drugs (FDA/CDER, 2002). The current draft can be viewed at. gov/cder/guidance/1221dft.htm. The study medication to be developed must conform to these guidelines, in whatever form may be current at the time the application is submitted. Ayahuasca as prepared and traditionally consumed in the Amazon is a decoction prepared from fresh plant materials that is consumed orally as a beverage. The suggested preparation under the IND protocol differs from the traditional preparation in that it will be a freeze-dried, aqueous extract made from fresh plant materials and administered in capsules. Although not ''traditional,'' this preparation can be more easily standardized and is likely to have longer term stability than an aqueous decoction. Moreover, use of a freeze-dried, encapsulated, standardized preparation will make the clinical and preclinical results more readily comparable with the work of). These investigators have set a standard of sorts since they are the only investigators so far to conduct clinical studies with ayahuasca. This extract can be standardized to contain a quantified amount of 3 of the known active alkaloids, viz., DMT, harmine, and THH. The methods will follow those described byin the preparation of a freeze-dried extract for clinical study. These investigators reported that 611 g of a freeze-dried, yellowish powder was obtained from a 9.6-L batch of Brazilian ayahuasca, which was used in that study. This represents a solid matter content of 63.6 g/L of soluble solutes from the decoction process. In the present study, we suggest a slightly different methodology be adopted from that followed byin that freeze-dried decoctions of each plant should be prepared separately and quantitatively analyzed. The separate extracts can then be combined in appropriate proportions based on the analytical data, such that the final extract will contain known concentrations of the key alkaloids, harmine, THH, and DMT. This method should minimize the inherent variability created by generating different batches of ayahuasca and then lyophilizing the whole extract. Final volumes and alkaloid concentrations of the combined extracts can be adjusted, if necessary, using inert excipient materials such as lactose. Advances in phytopharmaceutical technology over the past decade make the preparation of a standardized version of ayahuasca, in which the levels of active constituents are well-characterized, a relatively straightforward proposition. The challenge is to use methods that are similar to traditional indigenous methods of preparation, but carried out under a consistent and replicable protocol. To develop a replicable extraction and standardization procedure, some range-finding work will be needed using small batches of test material to determine the appropriate extraction parameters prior to scaling up to produce the test batch to be used in the study. Specifically, parameters such as the initial and final volumes of solvent (water) to be used, and the effect of boiling time, on the amount of soluble extractives and the alkaloid levels of the final, freeze-dried extract of each plant will need to be determined. Analytical methods, primarily thin-layer chromatography, and high-performance liquid chromatography can be used for the qualitative and quantitative characterization of each freeze-dried extract.
Once IND and IRB approvals have been obtained, the initial clinical study should focus on assessing safety in normal, healthy volunteers. Specific therapeutic outcomes must be deferred to a subsequent, Phase II study in an appropriate patient population. The therapeutic applications to be addressed will in part be determined by the data generated in the animal models and in the initial clinical study in healthy volunteers. In many respects, the objective of this initial study will be to replicate the results of the study ofto establish the safety and tolerability of the standardized ayahuasca preparation. An open-label (i.e., nonplacebo) dose escalation study design will be employed in a minimum of 12 subjects over a 12-week period, for a total of 6 doses per subject at 2week intervals. In this respect, the proposed dosing protocol differs from that employed by. In that study, subjects received a total of 4 doses of standardized extract ranging from 0 (placebo) to 1.0 mg/kg DMT/kg. Administration was single-blind, in that the doses were known to the investigators for safety reasons, but subjects were told they would receive 1 of 4 doses at random. In the IND study, we are proposing to administer a total of 6 doses at 2-week intervals over the 12-week course of the study. As with Riba et al.'s study, randomized low, medium, and high doses will be used in a single-blind design. This time course and dosing regimen will be used because it corresponds more closely to the anticipated therapeutic dosing regimen in a subsequent efficacy trial. Tablesummarizes the proposed clinical guidelines and parameters to be assessed in this initial Phase I safety study.
Step IV: subsequent clinical studies-efficacy of ayahuasca therapy for alcoholism If the safety and tolerability of ayahuasca is confirmed in the initial study as we anticipate it will be, then the efficacy trial should focus on a clear therapeutic objective. Based on the data generated by the Hoasca study, the treatment of alcohol dependence would appear to be the most logical target. In the UDV subjects in that study, cessation of alcohol use was linked to ingestion of hoasca tea in a supportive social context and to long-term elevations in the density of platelet 5-HT transporters. Ideally, a clinical efficacy study would seek to replicate these conditions to the extent possible. Candidates with a history of alcohol dependence should be selected for the study. In addition, neuroimaging technologies could be applied to prescreen the subjects for the existence of central serotonin transporter deficits. Subjects found to display the deficits, along with a behavioral history of alcohol dependence, could then be selected for inclusion in the study. The subject's response over the course of the treatment could be assessed by monitoring several parameters, including (1) rates of relapse with respect to drinking; (2) changes in personality, attitudes, and behavior as assessed in psychiatric interviews and by the application of assessment instruments such as the Tridimensional Personality Questionnaire, and (3) long-term modulation (presumably, elevation) of serotonin transporter densities measured with single photon emission computerized tomography or similar appropriate neuroimaging methodology. If supported by the preclinical and initial clinical data, secondary outcome measures might also include the assessment of immune response.
The reputation of ayahuasca as a jungle medicine and shamanic psychedelic plant concoction is nearly legendary, but scientific investigations by a variety of investigators over several decades have succeeded in elucidating much of the botany, chemistry, pharmacology, and ethnography that underlies the legend. Clinical investigations of its possible applications in psychiatric practices or in other healing modalities have been few, and formidable legal and technical challenges must be faced and overcome before further studies of its potential as a medicine can be investigated in appropriate clinical settings. It is to be hoped that the completion of recent, albeit preliminary, clinical studies in Brazil and Spain, and the possible approval of its use in a religious context, will open the door to further rigorous scientific investigations of ayahuasca's potential to heal.
Create a free account to open full-text PDFs.
Papers in Blossom that reference this study
dos Santos, T. C., de Araujo, D. B., Felippe, H. et al. · Chaos, Solitons & Fractals (2026)
Suay, D., Aicher, H. D., Kometer, M. et al. · NeuroImage (2025)
Halman, A., Kong, G., Sarris, J. et al. · Journal of Psychopharmacology (2023)
Perkins, D., Pagni, B. A., Sarris, J. et al. · Frontiers in Pharmacology (2022)
Madrid-Gambin, F., Gomez-Gomez, A., Busquets-Garcia, A. et al. · Biomedicine & Pharmacotherapy (2022)
Serra, Y. A., Barros-Santos, T., Anjos-Santos, A. et al. · Psychopharmacology (2022)
Barker, S. A. · Psychopharmacology (2022)
Schenberg, E. E., Gerber, K. · Transcultural Psychiatry (2022)
Perkins, D., Schubert, V., Simonová, H. et al. · Frontiers in Pharmacology (2021)
Uthaug, M. V., Mason, N. L., Toennes, S. W. et al. · Psychopharmacology (2021)
da Silva, M. G., Daros, G. C., de Bitencourt, R. M. · Behavioural Brain Research (2021)
O'shaughnessy, D. M., Berlowitz, I., Rodd, R. et al. · Therapeutic Advances in Psychopharmacology (2021)
Galvão-Coelho, N. L., Marx, W., Sinclair, J. et al. · Psychopharmacology (2021)
Goldberg, S. B., Shechet, B., Nicholas, C. R. et al. · Psychological Medicine (2020)
Netzband, N., Ruffell, S., Linton, &. S. et al. · Psychopharmacology (2020)
Krediet, E., Bostoen, T., Breeksema, J. J. et al. · International Journal of Neuropsychopharmacology (2020)
Jiménez-Garrido, D. F., Gómez-Sousa, M., Ona, G. et al. · Scientific Reports (2020)
Ona, G., Kohek, M., Massaguer, T. et al. · Journal of Psychoactive Drugs (2019)
Mello, S. M., Soubhia, P. C., Silveira, G. et al. · Journal of Psychoactive Drugs (2018)
Richards, W. A., Garcia-Romeu, A. · International Review of Psychiatry (2018)
Uthaug, M. V., Van Oorsouw, &. K., Kuypers, &. K. P. C. et al. · Psychopharmacology (2018)
Barker, S. · Frontiers in Neuroscience (2018)
Berro, L. F., Marinho, E. A. V., Cata-Preta, E. G. et al. · Frontiers in Pharmacology (2018)
Riga, M. S., Llad O-Pelfort, L., Artigas, F. et al. · Neuropharmacology (2017)
Lawn, W., Hallak, J. E., Crippa, J. A. et al. · Scientific Reports (2017)
Dakic, V., Nascimento, J. M., Sartore, R. C. et al. · Scientific Reports (2017)
Viol, A., Palhano-Fontes, F., Onias, H. et al. · Scientific Reports (2017)
Preller, K. H., Vollenweider, F. X. · Behavioral Neurobiology of Psychedelic Drugs (2016)
Barbosa, P., Strassman, R. J., da Silveira, D. X. et al. · Comprehensive Psychiatry (2016)
Garcia-Romeu, A., Kersgaard, B., Addy, P. H. · Experimental and Clinical Psychopharmacology (2016)
Tófoli, L. F., De Araujo, D. B. · International Review of Neurobiology (2016)
Kuypers, K. P. C., Riba, &. J., De La Fuente Revenga, &. M. et al. · Psychopharmacology (2016)
Frecska, E., Bokor, P., Winkelman, M. J. · Frontiers in Pharmacology (2016)
McKenna, D., Riba, J. · Current Topics in Behavioral Neurosciences (2016)
Kometer, M., Vollenweider, F. X. · Behavioral Neurobiology of Psychedelic Drugs (2016)
Favaro, V. M., Yonamine, M., Soares, J. C. K. et al. · PLOS ONE (2015)
Araújo, A. M., Carvalho, F. M., Carvalho, M. et al. · Archives of Toxicology (2015)
Szmulewicz, A. G., Valerio, M. P., Smith, J. M. · International Journal of Bipolar Disorders (2015)
Thomas, G., Lucas, P., Rielle Capler, N. et al. · Current Drug Abuse Reviews (2013)
Brown, T. K. · Current Drug Abuse Reviews (2013)
Bouso, J. C., González, D., Fondevila, S. et al. · PLOS ONE (2012)
Barbosa, P., Mizumoto, S., Bogenschutz, M. P. et al. · Drug Testing and Analysis (2012)
Barker, S., McIlhenny, E. H., Strassman, R. J. · Drug Testing and Analysis (2012)
Fábregas, J. M., González, D., Fondevila, S. et al. · Drug and Alcohol Dependence (2010)
Shen, H. W., Jiang, X. L., Winter, J. C. et al. · Current Drug Metabolism (2010)
Cakic, V., Potkonyak, J., Marshall, A. · Drug and Alcohol Dependence (2010)
Pires, A. P. S., De Oliveira, C. D. R., Moura, S. et al. · Phytochemical Analysis (2009)